BCM
ENTA icon

Bayesian Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bayesian Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,989
Closed -$234K – 487
2016
Q4 		$234K Buy
+6,989
New +$200K 0.06% 480

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
MCM
Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Bayesian Capital Management's ENTA Position: Q1 2017 in Review

Bayesian Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 6,989 shares — an estimated $234K sold.

Bayesian Capital Management first reported a position in ENTA in Q4 2016 and held it in 1 quarter. The position peaked at $234K in Q4 2016. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

  • Bayesian Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 6,989 Enanta Pharmaceuticals shares in Q1 2017, an estimated $234K.
  • Bayesian Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Bayesian Capital Management's Enanta Pharmaceuticals position peaked at $234K in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Bayesian Capital Management's 13F filing for Q1 2017, filed 15 May 2017.